Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia

Leukemia and Lymphoma

Volumn 50, Issue 8, 2009, Pages 1326-1332

  Nowakowska Kopera, Alicja ^a   Sacha, Tomasz ^a   Florek, Izabela ^a   Zawada, Magdalena ^a   Czekalska, Sylwia ^a   Skotnicki, Aleksander B ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

acute leukemia; minimal residual disease; WT1 gene

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR PROTEIN; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG FATALITY; FEMALE; GENE EXPRESSION; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WILMS TUMOR GENE 1; ACUTE DISEASE; ADOLESCENT; AGED; BIOSYNTHESIS; CHEMISTRY; COMPUTER SYSTEM; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; MYELOID LEUKEMIA; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; COMPUTER SYSTEMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, WILMS TUMOR; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; WT1 PROTEINS; YOUNG ADULT;

EID: 77649279888     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903050021     Document Type: Article

References (34)

1. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-520.
2. Rose EA, Glaser T, Jones C, et al. Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms' tumor gene. Cell 1990;60:405-508.
3. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (Wt 1) in human leukemias. Leukemia 1992;6:405-409.
4. Bruening W, Gros P, Sato T, et al. Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors. Cancer Invest 1993;11:393-399. (Pubitemid 23225914)
5. Rodeck U, Bossler A, Kari C, et al. Expression of the WT1 Wilms' tumor gene by normal and malignant human melanocytes. Int J Cancer 1994;59:78-82.
6. Silberstein GB, Van Horn K, Strickland P, et al. Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 1997;94:8132-8137. (Pubitemid 27343789)
7. Yang L, Han Y, Saurez Saiz F, et al. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007;21:868-876. (Pubitemid 46672061)
8. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (Wt 1) in human leukemias. Leukemia 1992;6:405-409.
9. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-3079. (Pubitemid 24328100)
10. Inoue K, Ogawa H, Yamagami T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996;88:2267-2278. (Pubitemid 26307931)
11. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (WT1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90:1217-1225. (Pubitemid 27314159)
12. Sugiyama H. Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia. Leuk Lymphoma 1998;30:55-61. (Pubitemid 28327255)
13. Ogawa H, Tsuboi A, Oji Y, et al. Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogenic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay. Bone Marrow Transplant 1998;21:525-527. (Pubitemid 28107962)
14. Gaiger A, Schmid D, Heinze G, et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998;12:1886-1894. (Pubitemid 28554462)
15. Kreuzer KA, Saborowski A, Lupberger J, et al. Fluorescent 5'-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias. Br J Haematol 2001;114:313-318. (Pubitemid 32762229)
16. Siehl JM, Reinwald M, Heufelder K, et al. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Ann Hematol 2004;83:745-750. (Pubitemid 39485544)
17. Yanada M, Terakura S, Yokozawa T, et al. Multiplex realtime RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia. Leuk Lymphoma 2004;45:1803-1808. (Pubitemid 38997147)
18. Cilloni D, Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 2004;112:79-84. (Pubitemid 38716252)
19. Cilloni D, Gottardi E, Saglio G. WT1 overexpression in acute myeloid leukemia and myelodysplastic syndromes. Methods Mol Med 2006;125:199-211.
20. Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002;16:2115-2121. (Pubitemid 35203456)
21. Garg M, Moore H, Tobal K, et al. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003;123:49-59. (Pubitemid 37222757)
22. Tamaki H, Mishima M, Kawakami M, et al. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol 2003;78:349-356. (Pubitemid 37532392)
23. Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003;101:1698-1704. (Pubitemid 36237562)
24. Ogawa H, Ikegame K, Kawakami M, et al. WT1 gene transcript assay for relapse in acute leukemia after transplantation. Leuk Lymphoma 2004;45:1747-1753. (Pubitemid 38997140)
25. Schmid D, Heinze G, Linnerth B, et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997;11:639-643. (Pubitemid 27241240)
26. Barragan E, Cervera J, Bolufer P, et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004;89:926-933. (Pubitemid 39049900)
27. Karakas T, Miething CC, Maurer U, et al. The coexpression of the apoptosis-related genes bcl-2 and WT1 in predicting survival in adult acute myeloid leukemia. Leukemia 2002;16:846-854. (Pubitemid 34537557)
28. Chiusa L, Francia di Celle P, Campisi P, et al. Prognostic value of quantitative analysis of WT1 transcripts in adult acute lymphoblastic leukemia. Haematologica 2006;91:270-271.
29. Weisser M, Kern W, Rauhut S, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005;19:1416-1423. (Pubitemid 41148947)
30. Ostergaard M, Olesen LH, Hasle H, et al. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol 2004;125:590-600. (Pubitemid 38747961)
31. Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues: WHO classification of tumours. Lyons, France: IARC Press; 2001.
32. Bennett JM, Catovsky D, Daniel MT. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American- British Cooperative Group. Ann Intern Med 1985;103:620-625.
33. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901-1928.
34. Greiner J, Schmitt M, Li L, et al. Expression of tumorassociated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006;108:4109-4117. (Pubitemid 44913282)